WASHINGTON / RankWire.AI / – A groundbreaking study published in the journal Science has identified a rare inherited genetic mutation that can elevate an individual’s overall risk of developing lung cancer by approximately 25 times, with non-smokers experiencing an increase of about 60 times, according to researchers’ findings. Conducted by scientists at the Dana-Farber Cancer Institute in collaboration with the 23andMe Research Institute, the research analyzed anonymized genetic data from over 3.3 million individuals. The investigators pinpointed the germline mutation, known as EGFR T790M, as one of the most potent inherited factors associated with lung cancer identified to date.
This mutation affects the epidermal growth factor receptor gene, which is responsible for controlling cell growth and division within lung tissue. While somatic mutations in EGFR acquired during a person’s lifetime are recognized as key drivers of non-small cell lung cancer, the T790M germline variation is inherited at birth and present in every cell. According to data from the National Cancer Institute, this mutation occurs roughly in 1 out of every 15,850 people in the United States. Lead author Dr. Jaclyn LoPiccolo pointed out that individuals carrying the variant have about a 62-fold increased likelihood of developing lung cancer if they are non-smokers, compared to approximately 11 times for those with a history of smoking.
Gene lineage tracing revealed that the EGFR T790M mutation is disproportionately concentrated in populations from the Southern Appalachian region, especially across Tennessee and Alabama. Evolutionary geneticists traced the mutation back to British and Irish settlers who migrated to North America during the colonial period, with its prevalence increasing following a population bottleneck about 200 years ago. Senior researcher Dr. Pasi A. Jänne emphasized that, although current lung cancer screening protocols primarily focus on tobacco exposure, discovering significant genetic risk factors may open doors for targeted low-dose computed tomography screening among non-smoking carriers.
Mutation Might Increase Lung Cancer Risk Up to 60 Times in Non-Smokers
Supported by both preclinical and clinical studies funded by the National Institutes of Health, the research confirmed that this mutation demonstrates a strong specific association with lung cancer, showing no significant link to 17 other common cancers examined in the dataset. Oncologists highlighted that, although tobacco use remains the primary cause of lung cancer overall, the rising incidence of lung cancer among non-smokers has become a significant global health concern. Companies such as AstraZeneca are actively developing targeted therapies like Tagrisso, a tyrosine kinase inhibitor, aimed at treating EGFR-mutated lung tumors once they progress.
Co-senior author Dr. Alexander Gusev remarked that the research illustrates how a single inherited point mutation can have an extraordinarily potent impact on disease susceptibility. Medical experts advise individuals with multiple relatives affected by lung cancer, unexplained multifocal lung nodules, or ancestral ties to Southern Appalachia to seek guidance from genetic counselors. The researchers underscored that possessing the mutation does not guarantee the development of lung cancer; environmental factors and additional genetic changes over a person’s lifetime significantly influence whether malignant transformation occurs.
Multicenter Study Analyzes Genetic Data from Over Three Million Participants
The consortium behind the study aims to broaden its observational efforts through the ongoing INHERIT Study, focusing on assessing other inherited variants of EGFR across diverse racial populations. The longitudinal research will seek to identify specific environmental triggers and secondary genetic modifications that determine why some carriers develop tumors while others remain unaffected.
Detailed results related to population genetics, risk assessments, and screening protocols will continue to be accessible through peer-reviewed medical repositories and institutional release platforms. Presentations of updated biomarker data at upcoming international oncology conferences are expected to guide future screening recommendations and clinical practices.